Segment Reporting – Significant Expense Disclosure (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2025

Dec. 31, 2024

Titan Pharmaceuticals Inc [Member]

Schedule of Segment Reporting Significant Expense

Amounts incurred for the above-identified expenses for the three months ended March 31, 2025 and 2024 were as follows:

	Three Months Ended March 31,
(in thousands of U.S. dollars)	2025		2024
Salaries and employee compensation benefits	$	15	$	415
Professional fees		315		397
Insurance expenses		110		124
Board of directors’ fees		39		81
Total	$	479	$	1,017

Amounts incurred for the above-identified expenses for the years ended December 31, 2024 and 2023 were as follows:

(in thousands of U.S. dollars)	2024		2023
Research and development costs	$	-	$	1,913
General and Administrative: Salaries and employee compensation and benefits		1,505		2,709
General and Administrative: Professional fees		1,628		1,538
General and Administrative: Insurance expenses		485		580
General and Administrative: Board of directors’ fees		457		476
Total	$	4,075	$	7,216